Subsequent in-vitro or in-vivo studies with scientific initiatives aiming at the TGF-β signaling pathway should be carried out to improve our understanding of the molecular pathogenesis of ACPs, with the perspective of developing potential targeted therapies against hypothalamus invasion and tumor progression (50). This evidence concerns the gene TGFB1 and acrocephalopolysyndactyly.